Reversal of Pulmonary Hypertension in a Human-Like Model: Therapeutic Targeting of Endothelial DHFR
Priya Murugesan(Yo San University), Hua Cai(University of California, Los Angeles), Chenggong Zong(University of California, Los Angeles), Chen Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yixuan Zhang(Chinese Academy of Sciences), Wenhui Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuan‐Li Huang(Asia University), Ji Youn Youn(University of California, Los Angeles), Joseph Loscalzo(Broad Institute)
Cited by 5
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.8k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k